Teva Pharmaceuticals Slumps to 453rd in Trading Volume Ranking Amid 30.79% Decline

On May 13, 2025, Teva Pharmaceutical Industries Ltd. (TEVA) experienced a significant decline, with its trading volume reaching $239 million, a 30.79% decrease from the previous day. This placed Teva at the 453rd position in terms of trading volume for the day. The stock price of Teva also dropped by 2.67%.

J.P. Morgan recently upgraded Teva Pharmaceutical to Overweight, setting a new price target of $23. This upgrade was based on the company's cost-cutting initiatives, which aim to achieve a 30% operating margin by 2027. The analyst, Chris Schott, highlighted that the $700 million cost-cutting program provides sufficient room for Teva to fund its pipeline programs while maintaining its branded products' growth potential. Drugs like Austedo, Olanzapine, and Duvakitug are expected to drive the company's growth in the coming years.

Schott's analysis also noted that Teva's strong position as a manufacturer of generic drugs, combined with its promising branded products and a cleaned-up balance sheet, makes the company a strong investment prospect. The upgrade from J.P. Morgan reflects a positive outlook on Teva's future, with analysts expecting a 3% increase in full-year 2025 revenue and a 2% improvement in per-share net income compared to 2024. For 2026, revenue is forecast to increase by less than 1%, but per-share net income is expected to rise by 9%.